Applied Filters
Teva charged in DoJ antitrust probe into generic drug price-fixing
Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.
Intercept sues Apotex over Ocaliva generic
Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute
A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Mylan launches Tecfidera generic amid Biogen battle
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
FDA approves Dr Reddy’s Vascepa generic
Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Teva sues Cipla over generic asthma inhalers
Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.
BMS, Pfizer secure victory over generic makers
In a victory for Bristol-Myers Squibb and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis.
Humira buyers appeal AbbVie ruling to Seventh Circuit
Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.
Ninth Circuit affirms California’s pay-for-delay ban
A US federal appeals court has refused to block California’s ban on pay-for-delay deals in the generic drugs industry.
Sun Pharma to pay $205m over generics price-fixing
A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.
